{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=High+Risk+NMIBC&page=2",
    "query": {
      "condition": "High Risk NMIBC",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=High+Risk+NMIBC&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-07-22T18:20:49.299Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT07322263",
      "title": "Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Bladder Cancer",
        "Non-Muscle Invasive Bladder Cancer (NMIBC)",
        "Urothelial Carcinoma",
        "Carcinoma in Situ (CIS)",
        "High-Grade Papillary Bladder Tumors",
        "BCG-Unresponsive Bladder Cancer",
        "Ta Stage Bladder Cancer",
        "T1 Stage Bladder Cancer",
        "BCG-Refractory Bladder Cancer",
        "High-Risk NMIBC",
        "Micropapillary Variant Urothelial Carcinoma (Favorable Subtype)"
      ],
      "interventions": [
        {
          "name": "Intravesical Gemcitabine and Docetaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Michael A. O'Donnell",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 174,
      "start_date": "2026-04-10",
      "completion_date": "2033-01-01",
      "has_results": false,
      "last_update_posted_date": "2026-04-17",
      "last_synced_at": "2026-07-22T18:20:49.299Z",
      "location_count": 1,
      "location_summary": "Iowa City, Iowa",
      "locations": [
        {
          "city": "Iowa City",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07322263"
    },
    {
      "nct_id": "NCT05538663",
      "title": "Intravesical BCG vs GEMDOCE in NMIBC",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Non-muscle-invasive Bladder Cancer"
      ],
      "interventions": [
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "Docetaxel",
          "type": "DRUG"
        },
        {
          "name": "Bacillus Calmette Guerin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ECOG-ACRIN Cancer Research Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 870,
      "start_date": "2023-02-07",
      "completion_date": "2030-10",
      "has_results": false,
      "last_update_posted_date": "2026-07-17",
      "last_synced_at": "2026-07-22T18:20:49.299Z",
      "location_count": 229,
      "location_summary": "Birmingham, Alabama • Fairbanks, Alaska • Gilbert, Arizona + 163 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Fairbanks",
          "state": "Alaska"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Goodyear",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05538663"
    },
    {
      "nct_id": "NCT02773849",
      "title": "ADSTILADRIN (=INSTILADRIN) in Patients With High-Grade, Bacillus Calmette-Guerin (BCG) Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Superficial Bladder Cancer"
      ],
      "interventions": [
        {
          "name": "ADSTILADRIN",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Ferring Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 157,
      "start_date": "2016-09-19",
      "completion_date": "2023-05-24",
      "has_results": true,
      "last_update_posted_date": "2024-07-29",
      "last_synced_at": "2026-07-22T18:20:49.299Z",
      "location_count": 34,
      "location_summary": "Gilbert, Arizona • Los Angeles, California • Denver, Colorado + 29 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02773849"
    },
    {
      "nct_id": "NCT05951179",
      "title": "Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Non-muscle Invasive Bladder Cancer"
      ],
      "interventions": [
        {
          "name": "TARA-002",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Protara Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 131,
      "start_date": "2023-09-15",
      "completion_date": "2032-03",
      "has_results": false,
      "last_update_posted_date": "2026-06-30",
      "last_synced_at": "2026-07-22T18:20:49.299Z",
      "location_count": 41,
      "location_summary": "Homewood, Alabama • Phoenix, Arizona • Queen Creek, Arizona + 35 more",
      "locations": [
        {
          "city": "Homewood",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Queen Creek",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05951179"
    },
    {
      "nct_id": "NCT04752722",
      "title": "LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Superficial Bladder Cancer",
        "Non-muscle Invasive Bladder Cancer With Carcinoma in Situ"
      ],
      "interventions": [
        {
          "name": "EG-70 (phase 1)",
          "type": "DRUG"
        },
        {
          "name": "EG-70 (phase 2) Master Protocol",
          "type": "DRUG"
        },
        {
          "name": "Surfactant Bladder Pre-Rinse and EG-70 (Substudy)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "enGene, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 350,
      "start_date": "2021-04-22",
      "completion_date": "2028-11-30",
      "has_results": false,
      "last_update_posted_date": "2026-06-22",
      "last_synced_at": "2026-07-22T18:20:49.299Z",
      "location_count": 50,
      "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 43 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Irvine",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04752722"
    },
    {
      "nct_id": "NCT06181266",
      "title": "A Phase 1/1b Study of ZH9 Treatment in Patients With Non-Muscle Invasive Bladder Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "NMIBC",
        "High Risk NMIBC",
        "Non Muscle Invasive Bladder Cancer"
      ],
      "interventions": [
        {
          "name": "ZH9",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Prokarium Ltd",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 22,
      "start_date": "2024-01-08",
      "completion_date": "2027-07-30",
      "has_results": false,
      "last_update_posted_date": "2025-08-19",
      "last_synced_at": "2026-07-22T18:20:49.299Z",
      "location_count": 4,
      "location_summary": "Bakersfield, California • Durham, North Carolina • Myrtle Beach, South Carolina + 1 more",
      "locations": [
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Myrtle Beach",
          "state": "South Carolina"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06181266"
    },
    {
      "nct_id": "NCT05943106",
      "title": "BCG in Combination With Durvalumab in Adult BCG-naïve, High-risk NMIBC Participants",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Non-Muscle- Invasive Bladder Cancer"
      ],
      "interventions": [
        {
          "name": "Durvalumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "BCG",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "130 Years",
        "sex": "ALL",
        "summary": "18 Years to 130 Years"
      },
      "enrollment_count": 100,
      "start_date": "2023-08-11",
      "completion_date": "2027-03-31",
      "has_results": false,
      "last_update_posted_date": "2026-05-26",
      "last_synced_at": "2026-07-22T18:20:49.299Z",
      "location_count": 19,
      "location_summary": "Phoenix, Arizona • Little Rock, Arkansas • San Diego, California + 16 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Lakewood",
          "state": "Colorado"
        },
        {
          "city": "Hialeah",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05943106"
    },
    {
      "nct_id": "NCT07000084",
      "title": "Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Recurrent Non-Muscle Invasive Bladder Carcinoma",
        "Stage 0a Bladder Cancer AJCC v8",
        "Stage I Bladder Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "BCG Solution",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Biopsy of Bladder",
          "type": "PROCEDURE"
        },
        {
          "name": "Cystoscopy",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Transurethral Resection of Bladder Tumor",
          "type": "PROCEDURE"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "Alliance for Clinical Trials in Oncology",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 330,
      "start_date": "2025-07-17",
      "completion_date": "2028-12-05",
      "has_results": false,
      "last_update_posted_date": "2026-07-02",
      "last_synced_at": "2026-07-22T18:20:49.299Z",
      "location_count": 58,
      "location_summary": "Birmingham, Alabama • Fairbanks, Alaska • Gilbert, Arizona + 51 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Fairbanks",
          "state": "Alaska"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Irvine",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07000084"
    },
    {
      "nct_id": "NCT02792192",
      "title": "Safety and Pharmacology Study of Atezolizumab Alone and in Combination With Bacille Calmette-Guérin (BCG) in High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) Participants",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Bladder Cancer"
      ],
      "interventions": [
        {
          "name": "Atezolizumab",
          "type": "DRUG"
        },
        {
          "name": "Bacille Calmette-Guérin",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2016-06-13",
      "completion_date": "2020-09-29",
      "has_results": true,
      "last_update_posted_date": "2021-10-28",
      "last_synced_at": "2026-07-22T18:20:49.299Z",
      "location_count": 8,
      "location_summary": "Stanford, California • Chicago, Illinois • Baltimore, Maryland + 5 more",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "The Bronx",
          "state": "New York"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02792192"
    },
    {
      "nct_id": "NCT04387461",
      "title": "Study of CG0070 Given in Combination With Pembrolizumab, in Non-Muscle Invasive Bladder Cancer, Unresponsive to Bacillus Calmette-Guerin",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Non Muscle Invasive Bladder Cancer"
      ],
      "interventions": [
        {
          "name": "CG0070",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pembrolizumab Injection",
          "type": "BIOLOGICAL"
        },
        {
          "name": "n-dodecyl-B-D-maltoside",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "CG Oncology, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 35,
      "start_date": "2020-12-08",
      "completion_date": "2024-05-28",
      "has_results": false,
      "last_update_posted_date": "2024-09-25",
      "last_synced_at": "2026-07-22T18:20:49.299Z",
      "location_count": 13,
      "location_summary": "La Jolla, California • Orange, California • Tampa, Florida + 9 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04387461"
    }
  ]
}